ITCI Insider Trading
ITCI | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at ITCI provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2021-01-06 02:09 | 2021-01-04 | Mates Sharon | Director, Officer - Chairman, President & CEO | OPT+S | $31.30 | 48,341 | $1,513,271 | 1,133,392 | 0.0% |
| 2021-01-06 02:11 | 2021-01-04 | Halstead Michael | Officer - EVP and General Counsel | OPT+S | $31.30 | 16,160 | $505,834 | 0 | 0.0% |
| 2020-11-20 04:05 | 2020-11-17 | Halstead Michael | Officer - EVP and General Counsel | OPT+S | $27.62 | 79,425 | $2,193,448 | 0 | 0.0% |
| 2020-11-14 01:51 | 2020-11-11 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $25.41 | 28,034 | $712,344 | 0 | 0.0% |
| 2020-11-13 01:51 | 2020-11-10 | Mates Sharon | Director, Officer - Chairman, President & CEO | SELL | $26.34 | 50,000 | $1,317,100 | 1,113,392 | -4.3% |
| 2020-11-07 02:00 | 2020-11-04 | Mates Sharon | Director, Officer - Chairman, President & CEO | SELL | $25.00 | 50,000 | $1,250,000 | 1,163,392 | -4.1% |
| 2020-10-16 23:04 | 2020-10-16 | Neumann Mark | Officer - EVP, Chief Commercial Officer | OPT+S | $26.80 | 6,792 | $182,026 | 28,120 | 0.0% |
| 2020-09-15 00:03 | 2020-09-14 | Alafi Christopher D | Director | BUY | $29.60 | 49,500 | $1,465,200 | 4,743,770 | +1.1% |
| 2020-09-12 02:08 | 2020-09-09 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $31.14 | 41,983 | $1,307,351 | 8,034 | 0.0% |
| 2020-09-11 23:15 | 2020-09-11 | Alafi Christopher D | Director | BUY | $28.08 | 21,000 | $589,680 | 4,694,270 | +0.4% |
| 2020-05-16 00:37 | 2020-05-14 | MARCUS JOEL S | Director | SELL | $20.04 | 9,602 | $192,424 | 39,140 | -19.7% |
| 2020-05-14 00:20 | 2020-05-11 | LERNER RICHARD A | Director | OPT+S | $20.50 | 3,500 | $71,750 | 93,813 | 0.0% |
| 2020-05-14 02:48 | 2020-05-11 | MARCUS JOEL S | Director | SELL | $20.04 | 57,297 | $1,148,037 | 48,742 | -54.0% |
| 2020-01-11 05:14 | 2020-01-09 | Satlin Andrew | Officer - EVP and Chief Medical Officer | OPT+S | $26.16 | 11,573 | $302,750 | 11,338 | 0.0% |
| 2020-01-11 05:09 | 2020-01-09 | Mates Sharon | Director, Officer - Chairman, President & CEO | SELL | $26.16 | 41,895 | $1,095,973 | 1,204,707 | -3.4% |
| 2020-01-11 05:03 | 2020-01-09 | Hineline Lawrence J. | Officer - SVP of Finance CFO | SELL | $26.16 | 19,638 | $513,730 | 18,800 | -51.1% |
| 2020-01-11 05:06 | 2020-01-09 | Halstead Michael | Officer - EVP and General Counsel | SELL | $26.16 | 19,638 | $513,730 | 191 | -99.0% |
| 2020-01-09 05:11 | 2020-01-06 | Mates Sharon | Director, Officer - Chairman, President & CEO | OPT+S | $30.28 | 45,598 | $1,380,881 | 1,144,707 | 0.0% |
| 2020-01-09 05:00 | 2020-01-06 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $30.29 | 21,458 | $650,004 | 18,800 | 0.0% |
| 2020-01-09 05:02 | 2020-01-06 | Halstead Michael | Officer - EVP and General Counsel | OPT+S | $30.34 | 21,458 | $651,008 | 191 | 0.0% |
| 2020-01-04 05:16 | 2020-01-02 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $32.43 | 7,807 | $253,165 | 19,800 | 0.0% |
| 2020-01-04 05:14 | 2020-01-02 | Mates Sharon | Director, Officer - Chairman, President & CEO | OPT+S | $32.45 | 17,478 | $567,231 | 1,144,707 | 0.0% |
| 2020-01-04 05:17 | 2020-01-02 | Halstead Michael | Officer - EVP and General Counsel | OPT+S | $32.43 | 7,807 | $253,214 | 191 | 0.0% |
| 2019-12-27 00:06 | 2019-12-23 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $25.50 | 15,032 | $383,316 | 19,800 | 0.0% |
| 2019-10-17 23:50 | 2019-10-16 | Neumann Mark | Officer - EVP, Chief Commercial Officer | OPT+S | $8.25 | 6,774 | $55,886 | 6,674 | 0.0% |
| 2019-09-11 23:30 | 2019-09-10 | Alafi Christopher D | Director, 10% owner | BUY | $10.26 | 485,000 | $4,974,694 | 4,673,270 | +11.6% |
| 2019-09-05 01:24 | 2019-08-30 | Alafi Christopher D | Director | BUY | $8.52 | 125,000 | $1,065,213 | 4,188,270 | +3.1% |
| 2019-06-20 00:48 | 2017-11-22 | Alafi Christopher D | Director | BUY | $15.55 | 10,000 | $155,500 | 3,963,270 | +0.3% |
| 2019-06-15 00:23 | 2019-06-12 | Alafi Christopher D | Director | BUY | $11.73 | 170,000 | $1,993,794 | 170,000 | +100.0% |
| 2019-05-16 01:03 | 2019-05-14 | Alafi Christopher D | Director | BUY | $12.56 | 100,000 | $1,256,350 | 4,053,270 | +2.5% |
| 2019-03-02 03:41 | 2019-02-27 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $15.00 | 1,000 | $15,000 | 25,232 | 0.0% |
| 2019-01-09 05:28 | 2019-01-04 | Mates Sharon | Director, Officer - Chairman, President & CEO | OPT+S | $11.58 | 52,202 | $604,311 | 1,138,707 | 0.0% |
| 2019-01-09 05:21 | 2019-01-04 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $11.58 | 24,566 | $284,383 | 17,032 | 0.0% |
| 2019-01-09 05:19 | 2019-01-04 | Vanover Kimberly E. | Officer - SVP, Early Stage Clinical Dev. | OPT+S | $11.52 | 10,156 | $116,979 | 27,068 | 0.0% |
| 2019-01-09 05:24 | 2019-01-04 | Halstead Michael | Officer - EVP and General Counsel | OPT+S | $11.58 | 24,566 | $284,418 | 191 | 0.0% |
| 2019-01-09 05:16 | 2019-01-04 | Davis Robert E | Officer - SVP, Chief Scientific Officer | SELL | $11.46 | 9,564 | $109,630 | 43,989 | -17.9% |
| 2019-01-04 05:02 | 2019-01-02 | Mates Sharon | Director, Officer - Chairman, President & CEO | OPT+S | $11.09 | 17,478 | $193,831 | 1,138,707 | 0.0% |
| 2019-01-04 04:46 | 2019-01-02 | Vanover Kimberly E. | Officer - SVP, Early Stage Clinical Dev. | OPT+S | $11.10 | 4,834 | $53,657 | 16,861 | 0.0% |
| 2019-01-04 04:23 | 2019-01-02 | Hineline Lawrence J. | Officer - SVP of Finance CFO | OPT+S | $11.09 | 7,807 | $86,580 | 17,032 | 0.0% |
| 2019-01-04 04:58 | 2019-01-02 | Halstead Michael | Officer - EVP and General Counsel | OPT+S | $11.09 | 7,807 | $86,580 | 191 | 0.0% |
| 2019-01-04 04:42 | 2019-01-02 | Davis Robert E | Officer - SVP, Chief Scientific Officer | OPT+S | $11.11 | 4,834 | $53,706 | 34,744 | 0.0% |
| 2018-12-08 00:44 | 2018-12-06 | Davis Robert E | Officer - SVP, Chief Scientific Officer | OPT+S | $13.53 | 899 | $12,163 | 30,256 | 0.0% |
| 2018-11-14 01:34 | 2018-11-09 | MARCUS JOEL S | Director | SELL | $18.17 | 32,000 | $581,581 | 78,742 | -28.9% |
| 2018-02-21 00:38 | 2018-02-15 | Hineline Lawrence J. | Officer - VP of Finance CFO | SELL | $20.02 | 49,700 | $995,163 | 17,032 | -74.5% |
| 2018-01-25 03:11 | 2018-01-22 | Halstead Michael | Officer - SVP and General Counsel | SELL | $18.03 | 25,500 | $459,765 | 191 | -99.3% |
| 2018-01-11 05:05 | 2018-01-08 | Vanover Kimberly E. | Officer - SVP, Clinical Development | SELL | $17.46 | 772 | $13,479 | 12,373 | -5.9% |
| 2018-01-11 05:01 | 2018-01-08 | Mates Sharon | Director, Officer - Chairman, President & CEO | SELL | $17.48 | 6,604 | $115,438 | 1,088,707 | -0.6% |
| 2018-01-06 04:19 | 2018-01-05 | Mates Sharon | Director, Officer - Chairman, President & CEO | OPT+S | $17.08 | 11,257 | $192,270 | 1,095,311 | 0.0% |
| 2018-01-06 04:14 | 2018-01-05 | Vanover Kimberly E. | Officer - SVP, Clinical Development | OPT+S | $17.37 | 1,185 | $20,583 | 13,145 | 0.0% |
| 2018-01-06 04:06 | 2018-01-04 | Hineline Lawrence J. | Officer - VP of Finance CFO | OPT+S | $16.34 | 5,062 | $82,725 | 66,732 | 0.0% |
How to Interpret $ITCI Trades
Not every insider transaction in ITCI is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ITCI shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for ITCI
Insider activity data for ITCI is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ITCI, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.